Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dr Reddys Laboratories (RDY) Accounts Payables (2017 - 2025)

Dr Reddys Laboratories (RDY) has 8 years of Accounts Payables data on record, last reported at $372.3 million in Q1 2024.

  • For Q1 2024, Accounts Payables rose 15.74% year-over-year to $372.3 million; the TTM value through Mar 2024 reached $372.3 million, up 15.74%, while the annual FY2024 figure was $373.5 million, 16.0% up from the prior year.
  • Accounts Payables reached $372.3 million in Q1 2024 per RDY's latest filing, up from $321.7 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $372.3 million in Q1 2024 and bottomed at $230.0 million in Q1 2020.
  • Average Accounts Payables over 5 years is $317.9 million, with a median of $325.6 million recorded in 2021.
  • Peak YoY movement for Accounts Payables: skyrocketed 41.61% in 2021, then dropped 5.41% in 2023.
  • A 5-year view of Accounts Payables shows it stood at $230.0 million in 2020, then surged by 41.61% to $325.6 million in 2021, then rose by 4.43% to $340.1 million in 2022, then dropped by 5.41% to $321.7 million in 2023, then increased by 15.74% to $372.3 million in 2024.
  • Per Business Quant database, its latest 3 readings for Accounts Payables were $372.3 million in Q1 2024, $321.7 million in Q1 2023, and $340.1 million in Q1 2022.